| Metabolic diseases such as sarcopenia (SP), osteoporosis (OP), and osteosarcopenia (OS), seriously threaten the physical and mental health of middle-aged and elderly people. Musculoskeletal attenuation disease is characterized by pathological loss of bone mineral density or muscle mass and function, which will lead to fracture, disability, and even death of patients. Although there are some achievements in the research of musculoskeletal diseases, comprehensive and systematic analysis of low-molecular-weight metabolites may effectively supplement the lack of gene, transcription, and protein information, and provide more information for systematic biological research. The dynamic changes of metabolites also make it possible to screen potential markers or targets of the musculoskeletal attenuation disease, thus providing new strategies and new ideas for the management of the musculoskeletal attenuation disease. Based on metabolomics, this article reviews the research progress in the clinical diagnosis, pathological mechanism, prevention and treatment of musculoskeletal attenuation disease. |